Shares of Cardiol Therapeutics Inc. (TSE:CRDL – Get Free Report) hit a new 52-week low during mid-day trading on Friday. The company traded as low as C$1.22 and last traded at C$1.23, with a volume of 68,664 shares. The stock had previously closed at C$1.25.
Cardiol Therapeutics Stock Down 2.4%
The company has a quick ratio of 6.84, a current ratio of 6.26 and a debt-to-equity ratio of 0.35. The business has a 50-day simple moving average of C$1.84 and a 200-day simple moving average of C$1.81. The company has a market cap of C$155.78 million, a PE ratio of -3.59 and a beta of 0.14.
Cardiol Therapeutics (TSE:CRDL – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported C($0.11) EPS for the quarter. Equities research analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 EPS for the current year.
Cardiol Therapeutics Company Profile
Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.
Further Reading
- Five stocks we like better than Cardiol Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
